Location History:
- Belfast BT5 6HZ, GB (1985)
- Macclesfield, GB (2005)
- Cheshire, GB (2002 - 2008)
Company Filing History:
3 out of 1,187 
1 out of 32 
1 out of 832,912 Years Active: 1985-2008
Title: Andrew E Parker: Innovator in Human Checkpoint Kinase Research
Introduction
Andrew E Parker is a notable inventor based in Cheshire, GB. He has made significant contributions to the field of biotechnology, particularly in the area of human checkpoint kinases. With a total of 5 patents to his name, Parker's work has implications for pharmaceutical development and cancer research.
Latest Patents
Among his latest patents, Parker has developed a novel human checkpoint kinase gene known as hCDS1. This invention includes the nucleic acid sequence of residues 66-1694 of SEQ ID NO: 1, along with a protein expressed from the gene, fragments, and functional equivalents of the protein. Additionally, he has created pharmaceutical compositions that utilize the hCDS1 protein, as well as methods for employing this protein in various applications. His work on hCDS1 also encompasses translated proteins, compositions, methods, and kits.
Career Highlights
Parker has had a distinguished career, working at prestigious institutions such as The Scripps Research Institute. His research has focused on advancing our understanding of checkpoint kinases and their potential therapeutic applications.
Collaborations
Throughout his career, Parker has collaborated with esteemed colleagues, including Walter H M L Luyten and Clare H McGowan. These partnerships have further enriched his research and contributed to the advancement of knowledge in his field.
Conclusion
Andrew E Parker's innovative work in the realm of human checkpoint kinases has positioned him as a key figure in biotechnology. His patents and research continue to pave the way for new therapeutic strategies in the fight against cancer.